Palantir loses crown as S&P’s top stock
Easy come, easy go.
Palantir’s 13% stumble since it reported pretty strong Q1 results means it’s lost its privileged position as the blue-chip index’s top-gaining stock in 2025. CVS Health is now back in the catbird seat.
Palantir, which was only added to the index last September, was the best performer in the S&P 500 in 2024, thanks to a 340% gain.
The defense, data, and AI software firm is still sitting on gains of more than 40% this year, compared to losses of 4.5% for the S&P 500 and 6% for the Nasdaq 100. (Not to mention losses of 16% and 32%, respectively, for fellow retail favorites Nvidia and Tesla.)
Not too shabby.